Adherex Licenses GSK’s Eniluracil, Estimates Oncologic’s Potential At $1 Bil.
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adherex gains rights to GlaxoSmithKline's oncology agent eniluracil in exchange for a GSK option on Adherex' lead biotechnology oncologic ADH-1 under a combined licensing agreement, announced July 15